Cochrane · systematic review · CD011831
Chlorpromazine versus penfluridol for schizophrenia
Nikvarz, N, Vahedian, M, Khalili, N · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 4 · 57.1%Very low 0 · 0%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Service utilisation: hospital admission (short term) | RR 0.19 [0.01, 3.6] | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |
Global state: clinically important change in global state | no estimate extracted | 0 studies · 0 participants | Ungraded |
Global state: relapse | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: clinically important change in mental state | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term) | RR 0.19 [0.04, 1.06] | 2 studies · 85 participants | Low Downgraded: risk of bias, imprecision |
Adverse effect/event: death | no estimate extracted | 0 studies · 2 participants | Ungraded |
Leaving the study early: any reason (medium term) | RR 1.21 [0.83, 1.77] | 3 studies · 130 participants | Low Downgraded: risk of bias, imprecision |